Cellular and T cell engager Immunotherapy
TALQUETAMAB, A GPRC5DXCD3 BISPECIFIC ANTIBODY, FOR TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA IN PATIENTS WITH PRIOR EXPOSURE TO BCMA TARGETED THERAPIES - A “REAL WORLD” STUDY
Eden Shkury
Medical intern, Division of Hematology and Bone Marrow Transplantation
Chaim Sheba Medical Center, Israel